(TMDX) TransMedics - Ratings and Ratios
Portable Organ Perfusion System, Lung, Heart, Liver Modules
TMDX EPS (Earnings per Share)
TMDX Revenue
Description: TMDX TransMedics
TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company that is revolutionizing the field of organ transplantation. The companys flagship product, Organ Care System (OCS), is a portable organ perfusion, optimization, and monitoring system that replicates near-physiologic conditions for donor organs outside the human body, increasing the chances of successful transplantation.
The OCS platform includes various products such as OCS LUNG, OCS Heart, and OCS Liver, which cater to different organ transplant needs. Additionally, the company offers a national OCS program, a turnkey solution for outsourced organ retrieval, and provides OCS organ management and logistics services, including transportation and coordination activities. With a strong presence in the US and international markets, TransMedics is poised for growth.
From a performance perspective, key KPIs to watch include revenue growth, gross margin expansion, and the number of OCS systems sold or leased. The companys ability to increase its market share in the organ transplantation market, expand its product offerings, and enhance its logistics and management services will be crucial in driving future growth. With a market capitalization of $3.56 billion and a return on equity (ROE) of 21.88%, TransMedics has demonstrated its ability to generate returns for shareholders.
To further evaluate the companys prospects, it is essential to monitor its research and development (R&D) pipeline, regulatory approvals, and competitive landscape. Key metrics such as the number of patents filed or granted, clinical trial results, and the competitive positioning of its OCS platform will provide insights into TransMedics ability to maintain its market lead and drive innovation.
TMDX Stock Overview
| Market Cap in USD | 3,691m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2019-05-02 |
TMDX Stock Ratings
| Growth Rating | 51.4% |
| Fundamental | 69.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -35.2% |
| Analyst Rating | 4.22 of 5 |
TMDX Dividends
Currently no dividends paidTMDX Growth Ratios
| Growth Correlation 3m | -40.9% |
| Growth Correlation 12m | 21% |
| Growth Correlation 5y | 86.6% |
| CAGR 5y | 38.04% |
| CAGR/Max DD 3y | 0.56 |
| CAGR/Mean DD 3y | 2.14 |
| Sharpe Ratio 12m | -1.20 |
| Alpha | 0.12 |
| Beta | 0.216 |
| Volatility | 62.54% |
| Current Volume | 778.1k |
| Average Volume 20d | 834.6k |
| Stop Loss | 113.8 (-5%) |
| Signal | 0.07 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (71.7m TTM) > 0 and > 6% of Revenue (6% = 31.9m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA 27.27pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 94.39% (prev 126.8%; Δ -32.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.13 (>3.0%) and CFO 115.3m > Net Income 71.7m (YES >=105%, WARN >=100%) |
| Net Debt (118.2m) to EBITDA (111.9m) ratio: 1.06 <= 3.0 (WARN <= 3.5) |
| Current Ratio 9.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (40.6m) change vs 12m ago 14.94% (target <= -2.0% for YES) |
| Gross Margin 59.79% (prev 60.66%; Δ -0.86pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 64.43% (prev 47.29%; Δ 17.14pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.97 (EBITDA TTM 111.9m / Interest Expense TTM 14.1m) >= 6 (WARN >= 3) |
Altman Z'' 3.47
| (A) 0.56 = (Total Current Assets 558.1m - Total Current Liabilities 56.6m) / Total Assets 890.5m |
| (B) -0.46 = Retained Earnings (Balance) -407.7m / Total Assets 890.5m |
| (C) 0.10 = EBIT TTM 84.3m / Avg Total Assets 824.5m |
| (D) 0.56 = Book Value of Equity 318.1m / Total Liabilities 572.4m |
| Total Rating: 3.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.97
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 0.46% = 0.23 |
| 3. FCF Margin 3.27% = 0.82 |
| 4. Debt/Equity 1.62 = 1.32 |
| 5. Debt/Ebitda 4.59 = -2.50 |
| 6. ROIC - WACC (= 4.85)% = 6.07 |
| 7. RoE 28.02% = 2.34 |
| 8. Rev. Trend 97.52% = 7.31 |
| 9. EPS Trend 77.81% = 3.89 |
What is the price of TMDX shares?
Over the past week, the price has changed by +11.15%, over one month by -4.65%, over three months by -12.03% and over the past year by -23.24%.
Is TransMedics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TMDX is around 127.67 USD . This means that TMDX is currently overvalued and has a potential downside of 6.56%.
Is TMDX a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TMDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 138.9 | 15.9% |
| Analysts Target Price | 138.9 | 15.9% |
| ValueRay Target Price | 139.3 | 16.2% |
Last update: 2025-09-11 04:51
TMDX Fundamental Data Overview
CCE Cash And Equivalents = 400.6m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 54.4121
P/E Forward = 47.619
P/S = 6.9478
P/B = 11.3148
Beta = 2.169
Revenue TTM = 531.3m USD
EBIT TTM = 84.3m USD
EBITDA TTM = 111.9m USD
Long Term Debt = 510.9m USD (from longTermDebt, last quarter)
Short Term Debt = 3.02m USD (from shortTermDebt, last quarter)
Debt = 513.9m USD (Calculated: Short Term 3.02m + Long Term 510.9m)
Net Debt = 118.2m USD (from netDebt column, last quarter)
Enterprise Value = 3.80b USD (3.69b + Debt 513.9m - CCE 400.6m)
Interest Coverage Ratio = 5.97 (Ebit TTM 84.3m / Interest Expense TTM 14.1m)
FCF Yield = 0.46% (FCF TTM 17.4m / Enterprise Value 3.80b)
FCF Margin = 3.27% (FCF TTM 17.4m / Revenue TTM 531.3m)
Net Margin = 13.49% (Net Income TTM 71.7m / Revenue TTM 531.3m)
Gross Margin = 59.79% ((Revenue TTM 531.3m - Cost of Revenue TTM 213.6m) / Revenue TTM)
Tobins Q-Ratio = 11.96 (Enterprise Value 3.80b / Book Value Of Equity 318.1m)
Interest Expense / Debt = 0.68% (Interest Expense 3.48m / Debt 513.9m)
Taxrate = 0.88% (316.0k / 35.8m)
NOPAT = 83.5m (EBIT 84.3m * (1 - 0.88%))
Current Ratio = 9.86 (Total Current Assets 558.1m / Total Current Liabilities 56.6m)
Debt / Equity = 1.62 (Debt 513.9m / last Quarter total Stockholder Equity 318.1m)
Debt / EBITDA = 4.59 (Net Debt 118.2m / EBITDA 111.9m)
Debt / FCF = 29.62 (Debt 513.9m / FCF TTM 17.4m)
Total Stockholder Equity = 255.7m (last 4 quarters mean)
RoA = 8.05% (Net Income 71.7m, Total Assets 890.5m )
RoE = 28.02% (Net Income TTM 71.7m / Total Stockholder Equity 255.7m)
RoCE = 10.99% (Ebit 84.3m / (Equity 255.7m + L.T.Debt 510.9m))
RoIC = 10.91% (NOPAT 83.5m / Invested Capital 765.4m)
WACC = 6.06% (E(3.69b)/V(4.21b) * Re(6.81%)) + (D(513.9m)/V(4.21b) * Rd(0.68%) * (1-Tc(0.01)))
Shares Correlation 3-Years: 93.94 | Cagr: 2.71%
Discount Rate = 6.81% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.43% ; FCFE base≈17.4m ; Y1≈21.4m ; Y5≈36.5m
Fair Price DCF = 18.22 (DCF Value 621.2m / Shares Outstanding 34.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 77.81 | EPS CAGR: 51.17% | SUE: 1.40 | # QB: 2
Revenue Correlation: 97.52 | Revenue CAGR: 93.32% | SUE: 1.00 | # QB: 2
Additional Sources for TMDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle